Within-Host Mathematical Models to Study Antibody Kinetics after the Prophylactic Ebola Vaccine in the Democratic Republic of the Congo

• Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

  2020 The Lancet Infectious Diseases article Medicine Viral Infections and Outbreaks Research Open access cited by 7 patents

  173

  citations
• Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

  2021 The Lancet Infectious Diseases article Medicine Viral Infections and Outbreaks Research Open access

  96

  citations
• Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

  2021 The Lancet Infectious Diseases article Medicine Viral Infections and Outbreaks Research Open access cited by 2 patents

  94

  citations
• Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment

  2020 Vaccine article Biochemistry, Genetics and Molecular Biology Virus-based gene therapy research Open access cited by 2 patents

  84

  citations
• Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

  2021 PLoS Medicine article Medicine Viral Infections and Outbreaks Research Open access cited by 1 patent

  69

  citations
• First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study

  2022 PLoS ONE article Medicine Viral Infections and Outbreaks Research Open access

  34

  citations
• Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability

  2023 Clinical Microbiology and Infection article Medicine Viral Infections and Outbreaks Research Open access

  27

  citations
• Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial

  2022 The Lancet Infectious Diseases article Medicine Viral Infections and Outbreaks Research Open access

  27

  citations
• A model for establishment, maintenance and reactivation of the immune response after vaccination against Ebola virus

  2020 Journal of Theoretical Biology article Medicine Viral Infections and Outbreaks Research Open access

  24

  citations
• Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial

  2024 The Lancet Infectious Diseases article Medicine Viral Infections and Outbreaks Research

  19

  citations
• Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone

  2023 The Lancet Global Health article Medicine Viral Infections and Outbreaks Research Open access

  18

  citations
• Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans

  2023 Frontiers in Immunology article Medicine Viral Infections and Outbreaks Research Open access

  17

  citations
• Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda

  2023 Vaccine article Medicine Viral Infections and Outbreaks Research Open access

  11

  citations
• Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

  2023 npj Vaccines article Medicine Viral Infections and Outbreaks Research Open access

  10

  citations
• Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo

  2023 The Journal of Infectious Diseases article Medicine Viral Infections and Outbreaks Research Open access

  9

  citations

15 results